Syndesi Therapeutics

Chemin Du Cyclotron 6

1348 Ottignies-Louvain-La-Neuve

BE

Syndesi Therapeutics

Foundation date

19/12/2017

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer’s Disease and other disorders with cognitive impairment.

Upcoming events

Latest news

  • Imec-onderzoekers leggen basis voor in vivo detectie van traag groeiende hersentumoren, met dank aan hyperspectrale camera

    Friday February 3rd 2023

  • Weber joins Vivactis Group to reinforce its Market Access capabilities

    Thursday February 2nd 2023

  • Mithra CDMO announces collaboration with VaRi Bioscience for the development of a long-acting product in women’s health

    Thursday February 2nd 2023